Abstract:The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 system, a groundbreaking innovation in genetic engineering, has revolutionized our approach to surmounting complex diseases, culminating in CASGEVY™ approved for sickle cell anemia. Derived from a microbial immune defense mechanism, CRISPR/Cas9, characterized as precision, maneuverability and universality in gene editing, has been harnessed as a versatile tool for precisely manipulating DNA in mammals. In the process of applying it to practice, the consecutive exploitation of novel orthologs and variants never ceases. It's conducive to understanding the essentialities of diseases, particularly cancer, which is crucial for diagnosis, prevention, and treatment. CRISPR/Cas9 is used not only to investigate tumorous genes functioning but also to model disparate cancers, providing valuable insights into tumor biology, resistance, and immune evasion. Upon cancer therapy, CRISPR/Cas9 is instrumental in developing individual and precise cancer therapies that can selectively activate or deactivate genes within tumor cells, aiming to cripple tumor growth and invasion and sensitize cancer cells to treatments. Furthermore, it facilitates the development of innovative treatments, enhancing the targeting efficiency of reprogrammed immune cells, exemplified by advancements in CAR-T regimen. Beyond therapy, it is a potent tool for screening susceptible genes, offering the possibility of intervening before the tumor initiative or progresses. However, despite its vast potential, the application of CRISPR/Cas9 in cancer research and therapy is accompanied by significant efficacy, efficiency, technical, and safety considerations. Escalating technology innovations are warranted to address these issues. The CRISPR/Cas9 system is revolutionizing cancer research and treatment, opening up new avenues for advancements in our understanding and management of cancers. The integration of this evolving technology into clinical practice promises a new era of precision oncology, with targeted, personalized, and potentially curative therapies for cancer patients.

Leukemia Treatment Based on CRISPR Genome-Editing Technology

Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Progress in the application of gene editing technology in cancer treatmentstaking CRISPR as an example

Cancer Research Using Crispr/Cas9 Gene Editing Technology

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

Harnessing the evolving CRISPR/Cas9 for precision oncology

A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy

The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy

CRISPR-Based Gene Editing: a Modern Approach for Study and Treatment of Cancer

Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy

The Applications of the CRISPR/Cas9 Gene-Editing System in Treating Human Diseases

Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

CRISPR-Cas9 in basic and translational aspects of cancer therapy

Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer

Application of CRISPR-Cas 9 system in cancer therapy

Insights into existing and futuristic treatment approach for chronic myeloid leukaemia

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy